Transcript segment

Baric Transcribed Interview (Redacted), p.111 · baric_ti:utt:00954

Date: 2026-04-10 09:00 (day precision)
Type: transcript segment · interview
recipient: Ralph S. Baric, Harry Kazenoff, David T. Lambeth III, William Henderson, Clark Ervin, Jake Greenberg
speaker: Christina Salazar

For DoD?

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

2026-04-10 09:00 Clark Ervin open

Commentary.
2026-04-10 09:00 Ralph S. Baric open

Thanks. A commentary piece that was published in Immunity, May 2020, that stated, equivocally, DC.Scheduling@LexitasLegal.com that it is unlikely that the lab leak hypothesis will go away because the safety procedures at the WIV, and I cited their paper where they worked with viruses at BSL-2.
2026-04-10 09:00 Christina Salazar open

Have you ever done any gain-of-function work for DARPA?
2026-04-10 09:00 Ralph S. Baric open

For DARPA? No.
2026-04-10 09:00 Christina Salazar

For DoD?
2026-04-10 09:00 Ralph S. Baric open

No.
2026-04-10 09:00 Christina Salazar open

For any other Federal agency?
2026-04-10 09:00 Ralph S. Baric open

Besides the NIH? I mean, technically, the work that we did with MERS, where we were given a waiver, as far as I know it was never really reviewed for GOF. It decided that it was in the national interest to develop a mouse model so that countermeasures could be developed against MERS. The virus has a 35 percent mortality rate. It could transmit to people, and it could transmit through asymptomatic spread. So there's a threat potential there. I think NIH made the right call in that case, that you develop the appropriate reagents so that you can move countermeasures forward to protect the public.
2026-04-10 09:00 Christina Salazar open

Okay. So have you ever done gain-of22 function research under any other federally funded grant?